Literature DB >> 17510533

Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma.

Kazumi Hagiwara1, Hirokazu Nagai, Yinghua Li, Haruhiko Ohashi, Tomomitsu Hotta, Hidehiko Saito.   

Abstract

ID4 is a member of the inhibitor of DNA binding (ID) family, and inhibits the binding of basic helix-loop-helix transcription factors to DNA. In some malignant tumors, ID4 is inactivated by promoter hypermethylation, and is thought to be a candidate tumor suppressor gene (TSG). We have found that the promoter region of the ID4 gene is frequently methylated in lymphoid cell lines (100%, 9/9), primary diffuse large B-cell lymphoma (95%, 19/20), and follicular lymphoma (100%, 10/10). Somatic mutation of the ID4 gene was also examined, and no mutations were found. These findings suggest that the ID4 gene might be inactivated by DNA hypermethylation, and may function as a TSG in malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510533     DOI: 10.3960/jslrt.47.15

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  16 in total

1.  Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Authors:  Colleen L Doçi; Tanmayi P Mankame; Alexander Langerman; Kelly R Ostler; Rajani Kanteti; Timothy Best; Kenan Onel; Lucy A Godley; Ravi Salgia; Mark W Lingen
Journal:  Int J Gynecol Pathol       Date:  2012-01       Impact factor: 2.762

2.  Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.

Authors:  Jan Harder; Michael J Müller; Matthias Fuchs; Vera Gumpp; Annette Schmitt-Graeff; Richard Fischer; Melanie Frank; Oliver Opitz; Jens Hasskarl
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.

Authors:  Marilyn L Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B Estrine; Norma J Nowak; Maria L Delioukina; Lawrence M Weiss; David D Smith; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

Review 4.  Inhibitor of differentiation 4 (ID4): From development to cancer.

Authors:  Divya Patel; Derrick J Morton; Jason Carey; Mathew C Havrda; Jaideep Chaudhary
Journal:  Biochim Biophys Acta       Date:  2014-12-12

Review 5.  Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.

Authors:  Sumedha Roy; Yuan Zhuang
Journal:  Front Med       Date:  2018-07-24       Impact factor: 4.592

6.  HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.

Authors:  Shujian Ge; Dan Wang; Beibei Lv; Shuping Yang; Chunmei Liu; Bin Xu; Chunming Zhao; Yejun Qin; Jiawen Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

7.  ID4: a new player in the cancer arena.

Authors:  Stefania Dell'Orso; Federica Ganci; Sabrina Strano; Giovanni Blandino; Giulia Fontemaggi
Journal:  Oncotarget       Date:  2010-05

8.  Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells.

Authors:  Carolin Manthey; Demissew S Mern; Anja Gutmann; Anne J Zielinski; Corinna Herz; Silke Lassmann; Jens Hasskarl
Journal:  BMC Cell Biol       Date:  2010-01-14       Impact factor: 4.241

9.  Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Eric Smith; Neville J De Young; Sandra J Pavey; Nicholas K Hayward; Derek J Nancarrow; David C Whiteman; B Mark Smithers; Andrew R Ruszkiewicz; Andrew D Clouston; David C Gotley; Peter G Devitt; Glyn G Jamieson; Paul A Drew
Journal:  Mol Cancer       Date:  2008-10-02       Impact factor: 27.401

10.  Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.

Authors:  Nicole Bethge; Ragnhild A Lothe; Hilde Honne; Kim Andresen; Gunhild Trøen; Mette Eknæs; Knut Liestøl; Harald Holte; Jan Delabie; Erlend B Smeland; Guro E Lind
Journal:  Epigenetics       Date:  2013-12-20       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.